arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Kalaris Therapeutics, Inc.

KLRS
$2.35 ▲ +0.32 (+15.76%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
31 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

Kalaris Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $55.9M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -17.0% ↘
FCF / Share $-0.46 ↗
Trailing P/E —
Price / Book 1.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-10.86M
↓ -6.5% —
FCF / Share Free cash flow per share
$-0.46
↑ +4.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
15
Financial Health ↑
20
Cash Quality ↑
60

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 31 quarters